Drug Trial Radar · NCT00002935
Photodynamic Therapy in Treating Patients With Early Esophageal Cancer
Last checked: Nov 19, 2026Latest source record: Dec 23, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Oct 1995
Primary completion
Aug 2006
Study completion Sep 2007
Sponsor
- Lead sponsor
- Roswell Park Cancer InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 22, 2003
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. This may be an effective treatment for esophageal cancer. PURPOSE: Phase II trial to study the effectiveness of photodynamic therapy in treating patients with Barrett's esophagus who have in situ esophageal cancer.
Conditions
- Esophageal Cancer
Interventions
porfimer sodiumDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Roswell Park Cancer Institute
Buffalo, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.